Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a pioneer in cellular metabolism and pyruvate kinase (PK) activation therapies, unveiled detailed results from the Phase 3 ENERGIZE study of mitapivat for non-transfusion-dependent (NTD) alpha- or beta-thalassemia. The findings, presented at the European Hematology Association 2024 (EHA2024) Hybrid Congress in Madrid, Spain, demonstrated significant improvements in hemoglobin levels and […]
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), renowned for its innovative therapies in cellular metabolism and pyruvate kinase (PK) activation, has announced promising results from its global Phase 3 ENERGIZE-T study. The study focused on mitapivat, a novel treatment for adults with transfusion-dependent alpha- or beta-thalassemia, achieving its primary endpoint of significant transfusion reduction, along with all […]
Agios Pharmaceuticals has secured approval for PYRUKYND (mitapivat) from the US Food and Drug Administration (FDA) for the treatment of hemolytic anemia in adult patients having pyruvate kinase (PK) deficiency. PYRUKYND is an oral pyruvate kinase activator, which is now the first approved disease-modifying therapy for the rare, debilitating, lifelong hemolytic anemia. The FDA approval […]
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals for Tibsovo (ivosidenib), designed for the treatment of acute myeloid leukemia (AML) in patients exhibiting specific genetic mutations and whose condition is either relapsed or refractory. This marks a significant advancement in the targeted therapy landscape for AML. Tibsovo, an isocitrate dehydrogenase-1 […]
The US Food and Drug Administration (FDA) has granted approval to Agios Pharmaceuticals’ TIBSOVO (ivosidenib) for the treatment of adult patients with acute myeloid leukemia (AML) who have relapsed or refractory conditions and are confirmed to have an isocitrate dehydrogenase-1 (IDH1) mutation. This approval marks a significant advancement in targeted cancer therapy, offering new hope […]
